NCT01757613View on ClinicalTrials.gov

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Actinic Keratosis Olsen Grade I/II
Interventions
DRUG

AK 3012

cutaneous use twice a day

Trial Locations (9)

22391

Hamburg

70178

Stuttgart

70190

Stuttgart

70499

Stuttgart

72076

Tübingen

78315

Radolfzell

88045

Friedrichshafen

89129

Langenau

89143

Blaubeuren Abbey

All Listed Sponsors
collaborator

CenTrial GmbH

INDUSTRY

collaborator

d.s.h. statistical services GmbH

UNKNOWN

lead

Dolorgiet GmbH & Co. KG

INDUSTRY

NCT01757613 - Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis | Biotech Hunter | Biotech Hunter